Date: 2015-03-17
Type of information: Termination of the agreement
Compound: GLPG1690
Company: Galapagos (Belgium) Janssen Pharmaceutica, a J&J company (USA - NJ)
Therapeutic area: Inflammatory diseases - Lung diseases - Respiratory diseases
Type agreement: termination of the licensing agreement
Action mechanism: enzyme inhibitor/autotaxin inhibitor. GLPG1690 has a novel mode of action discovered by Galapagos, with potential application in pulmonary diseases. Galapagos identified autotaxin as playing a key role in inflammation, using an inflammation assay in its unique target discovery platform. Pharmacology and translational studies published by other parties in the literature since then suggest autotaxin may play a key role in metabolic disease, arthritic pain, oncology, and lung disease. GLPG1690 is a potent and selective inhibitor of autotaxin. In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement.
Disease: idiopathic pulmonary fibrosis
Details: * On March 17, 2015, Galapagos announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies. In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs. These programs are based on novel targets for inflammatory disorders that were identified and validated by Galapagos using its proprietary target discovery engine. Subsequent Galapagos research led to the discovery of GLPG1690, a first-in-class molecule that entered the clinic for inflammatory disorders. Galapagos views the molecules emerging from the alliance as strong additions to its growing proprietary pipeline. Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, return to Galapagos. Galapagos has successfully completed a First-in-Human Phase 1 trial for GLPG1690 and is preparing a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF), to be filed for approval before the end of 2015.
Financial terms:
Latest news:
